
The retrospective cohort study examined the impact of monoclonal antibody therapy (mAB) on end-of-life healthcare utilization and costs for advanced head and neck cancer patients aged 65 and over. The results showed that mAB therapy was associated with higher emergency department visits and healthcare costs, potentially due to infusion-related and drug toxicity expenses. Only 2.2% of the 12,544 patients with head and neck cancer utilized mAB therapy at the end-of-life period.
Like
Save
Share